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Abstract
Today, there are over 250 drugs being used to cure over 100 different types of cancer. We hypothesize that
one of the drugs already being used in cancer treatment will either show positive or negative growth when
applied specifically to glioblastoma, a type of brain tumor with poor prognosis. Using the fruit fly,
Drosophila melanogaster, and 150 tyrosine kinase inhibitors, we can induce tumors and track their growth
in response to the drugs. This would open the doors to researching similarities between drugs present in
hundreds of chemical libraries. Additionally, the drugs that prove successful through the screenings could
start being used in mammalian and clinical trials in the future.
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Chapter 1
History of Drosophila

Drosophila has been proven to be a useful model organism in the scientific field since it
was first used in 1901 by Thomas Hunt Morgan (Jennings, 2011). Jennings states in her
research that Morgan, along with many other scientists, found Drosophila more
beneficial than vertebrae models for a number of reasons, including they are easy and
inexpensive to culture in laboratory conditions, have a much shorter life cycle of about 12
days, represented in Figure 1, and they produce large numbers of externally laid embryos
that can be genetically modified. Morgan used the defining of genes and ability to
establish that they were on the chromosomes to further define the theory of inheritance
that was proposed by Gregor Mendel (Jennings, 2011). It was this redefining that led
Morgan to receive The Nobel Prize of Physiology or Medicine in 1933 for “his
discoveries concerning the role played by the chromosome in heredity” (“Nobel Prize and
Literature”, 2018). This Nobel Peace Prize opened the doors to different research that
could be conducted using Drosophila, and it was this continuation of research that went
on to win many other awards of their own. This is demonstrated through the findings of
Jeffery C. Hall, Michael Rosbash and Michael W. Young, who in the 1980s discovered
the molecular mechanism that controls circadian rhythms using this model organism
(Huang, 2018). Areas of their research concerned the rapid reproduction of recombinant
DNA, which allowed them to both characterize and clone the Drosophila clock gene
named period independently. It is this rich legacy of past research that allows this model
organism to be used for comparisons to continually be made between different biological
diseases as well as other physiological differences.
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Fig. 1. Lifecycle of Drosophila Melanogaster: For both
male and female flies, they go through 5 different growth
stages, starting with the embryo and ending with pupa.
Image from: Creative Diagnostics, 2009-2018.
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Comparisons Between Drosophila and Humans

Besides the ability to easily induce desired genetic pathways, Drosophila also makes a
good model organism due to it sharing 70% of disease genes with humans (Read et al.
2009). Drosophila has approximately 13,600 genes in its genome, which was sequenced
for the first time in 2000 (Mark et al. 2000). Of these 13,600 genes, there was a separate
study completed that looked at the 929 human disease genes that were associated with at
least one mutant allele discovered in Drosophila’s own genome (Reiter et al. 2001). The
OMIM, or Online Mendelian Inheritance in Man, was used as the human comparison
group. In Reiter et. al. research they found that of the 929 OMIM genes, 714 contain
highly similar (E ≤10−10) cognates in Drosophila (77%). The researchers created a
database, appropriately named Homophila, to build the connection between Drosophila
and humans, allowing for the variety of many successful experiments to be conducted in
the future. A subset of shared genes are illustrated in Figure 2, which represent the
different cancer types that can be a modelled using Drosophila.
In the past, other research has been conducted that focused on the genetic comparisons
between Drosophila and human disease (Fortini et al. 2000; Rubin et al. 2000). Although
these studies all proved successful, they were a more restrictive study than that performed
by Reiter et. al., only looking at a subset of 289 linked genes. Fortini and Rubin’s
research does not take into account the remaining 425 genes (when compared to the
linked 714 in Reiter’s study), nor do they examine the vast possible genetic effects of the
found 289 genes. Fortini and Rubin in their studies further solidified the genetic
connection between Drosophila and humans, but a much wider gene pool was necessary
for the most accurate data.
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Figure 2. Illustration of tumor expression in Drosophila. Tumors ranging from Imaginal Disks,
Brain, Muscle, and Haemo-lymph tumors can be expressed. These can be further divided into
sub-tumors as listed on the right along with the type of pathways used for each. Showcases
how Drosophila is a top-tier model organism for expressing the wanted tumors. Figure from
Villegas, 2017.
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Inducing Glioma in Drosophila
The model of glioma that can be replicated repeatedly in Drosophila is useful in studying
the possible causes, as well as changes that can act as inhibitors to the tumor growth. The
fly brain is composed of two dorsal hemispheres and the ventral nerve cord, that forms
the central nervous system of the fly. The CNS is mainly comprised of neuron and glia
that make up ~10% of cells in the fly CNS (Witte et al., 2011). This substantial
percentage gives good insight into what makes glioblastoma so malignant, given the fact
it is a glial driven tumor. Other areas that Witte, Jeibmann, etc. cover in their research
are the pathways that can be induced in Drosophila to effectively produce glioma. They
found promising molecular targets for therapeutic intervention included the tyrosine
kinase receptors epidermal growth factor receptor (EGFR), platelet-derived growth factor
receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR) and their
downstream signaling cascades, the phosphatidylinositol 3-phosphate kinase (PI3K)/AKT
and Ras/mitogen-activated protein kinase pathway (Witte et al. 2009). Additionally, it
was found that using the GAL4-UAS system proved the most effective when testing
possible pathways to inhibit glioma via different measures, and this is shown in Figure 3.
Although this research does exhibit the GAL4-UAS system as an effective pathway, it
does not fully explain what aspects of this pathway led them to choosing it for their
research.
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Figure 3. Optical projections of whole brain-ventral nerve cord complexes from late 3rd instar
larvae approximately 130 hr AED, displayed at the same scale. Dorsal view; anterior up. Each
brain is composed of 2 symmetrical hemispheres attached to the ventral nerve cord (VNC). In
repo>dEGFRλ;dp110CAAX larvae, both brain hemispheres and the VNC are enlarged and
elongated relative to other genotypes. Figure by Read et al., 2009.
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The P13K Ras Pathway

The three core signaling pathways that are commonly activated in glioma patients are
the tumor protein p53 [p53] pathway, the receptor tyrosine kinase/Ras/phosphoinositide
3-kinase signaling pathway, and the retinoblastoma pathway (Davis, 2016). Despite these
separate pathways, the EGFR-Ras and PI3K pathway continues to be one of the most
effective models, as shown in Figure 4. The mutation or amplification of the Epidermal
Growth Factor Receptor (EGFR) tyrosine kinase continually shows the most frequent
genetic damage in gliomas, as stated in Read et al. research concerning this specific
pathway. The network EGFR-Ras/ PI3K pathway coordinately stimulates oncogenic
behaviors, such as, cell cycle entry and progression, protein translation, and inappropriate
cellular growth and migration. The article states that it is these behaviors exhibited in the
coactivation of these pathways that creates tumor-like growths that mimic human glioma,
which is what makes it so useful in a laboratory setting. When PI3K Ras pathway was
activated using the repo-Gal4 driver, it induced an accumulation of ~50-fold excess glia
(Read et al. 2009). In spite of their being different pathways initiated to produce glioma,
in Read et al. study they found glial-specific coactivation of EGFR-Ras and PI3K
stimulated glial neoplasia, giving rise to CNS enlargement and malformation, neurologic
defects, and late larval lethality.
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Figure 4. Overview of the PI3K/AKT/mTOR pathway and drug targets. Activating nodes (PI3K, AKT,
PDK1, mTORC1 and mTORC2) and negative regulators (PTEN, TSC complex) are highlighted. Interaction
with RAS and LKB1/AMPK pathways is also displayed.
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Tyrosine Kinase Function
Tyrosine kinases are a family of enzymes, which use ATP to catalyze phosphorylation of
select tyrosine residues in target proteins. It is these enzymes, through covalent posttranslational modification, that act as a key component of normal cellular communication
and maintenance of homeostasis (Paul & Mukhopadhyay, 2004). Some of these cellular
functions include: cell proliferation, differentiation, migration, metabolism and
programmed cell death. Paul and Mukhopadhyay go on in their research of tyrosine
kinases to state that it is the ligand binding to the kinase’s extracellular domain that
triggers a response, as seen in Figure 5. These ligands are extracellular signal molecules
(e.g. EGF, PDGF etc.) that induce receptor dimerization, which is a chemical reaction
that joins two molecular subunits, forming a dimer (Chemistry LibreTexts, 2017)

There are two separate classifications of Tyrosine Kinases, either Receptor Tyrosine
Kinase (RTK) or non-receptor tyrosine kinase (NRTK). The RTK are cell surface
transmembrane receptors that also possess kinase activity. Paul and Mukhopadhyay
found in their research that the RTK are ligand specific, contain a single pass
transmembrane hydrophobic helix and a cytoplasmic portion with a tyrosine kinase
domain. NRTK are cytoplasmic proteins, that contain a kinase domain and possess
several additional signaling or protein-protein interacting domains (Paul &
Mukhopadhyay, 2004). It was found that the activation mechanism of NRTK is more
complex than that of RTK, which they hypothesized made the RTK more frequently
activated.

Tyrosine kinases activity are tightly regulated in normal cells, but they have the ability to
acquire transforming functions due to mutation(s), overexpression and autocrine
paracrine stimulation, leading to malignancy (Paul & Mukhopadhyay, 2004). It is these
different functions that the kinase takes on that allow it to represent a major portion of the
oncoproteins that play a powerful role in the plethora of cancers, which includes glioma.
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Figure 5. Mechanism of action of tyrosine kinase. 1. Receptor expression at membrane claveola 2. Ligand
binding occurs 3. Hetero/homodimerization leads to tyrosine kinase activation and tyrosine
transphosphorylation 4. Signal transduction throughout the cell 5. Receptor internalization 6. Receptor
activates response of either degradation or re-expression. Figure by Paul & Mukhopadhyay, 2004.
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Tyrosine Kinase Role in Cancer

To ensure normal tissue patterning in an organism, there must be tight control of cell
proliferation and morphogenesis in conjunction with programmed apoptosis. It is when
imbalances occur within these cell signals that oncogenesis can occur (Sangwan & Park,
2006). As stated in earlier research (Mukhopadhyay & Paul, 2004), it is the more
frequently activated RTKs that have the potential to cause dimerization to the kinases,
and this change in conformation leads to activation of the kinase and
transphosphorylation of the receptor on specific tyrosine residues. The phosphorylated
tyrosine residues are a critical aspect because they provide docking sites on the receptor
for signaling proteins, and it is these signaling proteins that act to relay the signal from
the receptor into the cell. When these signaling pathways become altered through
mutations or chromosomal translocation, the RTKs can deliver a continuous or enhanced
signal, forming it into a potent oncogene (Sangwan & Park, 2006). As of 2001, 58 genes
encoding RTKs have been identified in the human genome, 30 of which have been found
to be dysregulated in human cancers (Blume-Jensen & Hunter, 2001). Different
discovered tyrosine kinases inhibitors are shown in Figure 6.

Together with these behaviors, Sangwan and Park (2006) found that growth-factor
stimulation within a cell also aids in producing oncogenic behaviors. It is the nonscheduled expression of these growth factors that may result in a constant stimulation of
cell growth in addition to a block in apoptosis. The combination of the mis-regulated
RTKs and growth factors plays a critical role in regulating the tumor microenvironment,
by enhancing both the proliferation and invasion by tumor cells. This invasion of tumor
cells can form lung, breast, and brain cancer, and Sangwan & Park in their research go to
explain how the pathways are initiated, and also possible routes that can be taken to halt
the tumor progression in its track.
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Figure 6. These are structures of some of the important kinase inhibitors discovered so far. Figure by
Grant, 2008.
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Tyrosine Kinase Expression in Drosophila

Through the sequencing completed by the Human Genome Project, it was found that the
human genome contains 90 tyrosine kinases (Robinson et al., 2000). Of these 90 tyrosine
kinases, 58 are the receptor types (RTKs). Of this large amount of RTKs present in the
human genome, only 20 RTKs have been identified in the Drosophila genome. Just like
what has been found in human kinases, these different receptors share many of the same
effectors and their hierarchical organization is retained in biological contexts (Sopko &
Perrimon, 2013). While in their research they may have found this to be true for the
identified Drosophila tyrosine kinase receptors, very little is still known for
approximately half of them.

Of the many pathways that RTKs can signal in the Drosophila genome, the one most
commonly linked to glioma is the Epidermal Growth Factor Receptor (EGFR). EGFR
plays a multitude of roles inside the genome, such as dorsal/ventral patterning of the
embryonic ectoderm, establishment of neuroectoderm, wing development, photoreceptor
differentiation, and the specification of muscle precursors (Sopko & Perrimon, 2013). It
is able to signal these specific pathways by predominantly mediating short-range
signaling that is restricted to cells producing EGF or to cells positioned 1-2 cells away. A
pathway that falls into this category is the Ras/Raf/MEK/ERK pathway, showcased in
Figure 7. There are four EGFR ligands in Drosophila: Spitz, Keren, Gurken, and Vein,
and Sopko & Perrimon found in their study that all four play a critical role in the
signaling of the pathway. By monitoring these different ligands and sub-pathways in
EGFR, Sopko and Perrimon opened up the research field to possibly triggers or onsets of
diseases, such as ones like glioma.
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Figure 7. Activation of Ras/Raf/MEK/ERK signaling pathway. RTK, receptor tyrosine kinase;

SOS, mammalian son-of-sevenless; Shc, homology 2 domain-containing protein; MEK,
mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase.
Figure by Yang & Yang, 2017.
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Success of Tyrosine Kinase Inhibitors with Glioma

The modes of oncogenic activation can be targeted using different approaches for
tyrosine kinase inhibition, such as, small molecule inhibitors, monoclonal antibodies, heat
shock proteins, immunoconjugates, antisense and peptide drugs (Mukhopadhyay, Paul
2004). The small-molecule compounds that inhibit the kinase domain have recently
changed clinical practice for several cancers. Lapatinib has shown positive effects in
HER2-positive metastatic breast cancer (Geyer et al., 2006); sunitinib positively
influences metastatic renal-cell carcinoma (Motzer et al., 2007); and sorafenib is
beneficial in carcinoma treatment due to it inhibiting the targeted kinase domain (Joseph
et al., 2008). Taking this knowledge on the kinase inhibitors that work, De Witt Hammer
(2010) systematically reviewed the efficacy, toxicity, and tissue analysis of smallmolecule kinase inhibitors in adult patients with glioblastoma as reported in published
clinical studies. De Witt Hammer also determined which kinases have been targeted by
the inhibitors used in these studies, by using publications from a MEDLINE search. From
the search, 60 studies qualified for inclusion, and 2385 glioblastoma patients receiving
kinase inhibitors could be evaluated. The extracted data included radiological response,
progression-free survival, overall survival, toxicity, and biomarker analysis. This data
could be analyzed to determine the overall effects of kinase inhibition from past studies,
by looking at the effects it showed on the patients during and after treatment.

De Witte Hammer found through analysis that (i) efficacy of small-molecule kinase
inhibitors in clinical studies with glioblastoma patients does not yet warrant a change in
standard clinical practice and (ii) 6 main kinase targets for inhibitors have been evaluated
in these studies: EGFR, mTOR, KDR, FLT1, PKCβ, and PDGFR. Although in this study
the promise of kinase inhibitors being effective in cancer treatment was not strong, De
Witte Hammer overlooks the fact that there are many limitations to his study. Some of
these limitations include, not having a control group, small sample sizes, and many of the
60 studies were not designed to determine the efficacy of therapy. The efficacy of the
therapy is especially important, because by not having that the pathobiology of the drug
may not be accurately studied in glioblastoma patients, along with the inhibitor may have
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failed to inactivate the target in glioblastoma cells. Knowing the efficacy would aid to
ruling out these errors and producing more accurate studies in the future.
Different from De Witte Hammer’s study (2010), Mellinghoff et al. (2012) looked more
specifically at how kinase inhibitors perform as glioblastoma drugs, specifically when
targeting the PI3K pathway. Throughout their study they look at results from clinical
trial, the structure of the human genome, and techniques that can be applied to
glioblastoma to halt tumor growth. The clinical study looked specifically at mTOR,
which was the first member of the PI3K pathway for which a clinical grade inhibitor
became available, and its effect on patients with PTEN-deficient, recurrent glioblastoma
(Podsypanina et al., 2001). After 1-2 weeks, the effect that inhibition of mTOR had on
glioblastoma was analyzed, and it was found that although there was reduction of
neoplasia, it was not enough to cause effective change on the tumor. Although these
results do not seem promising, it must be taken into account that the information was
preliminary because tumors with the most informative genotype(s) and strong basal
pathway activation were generally underrepresented in the studies and because of
difficulties to assemble a sufficient drug-naive “control” tumor sample (Mellinghoff et
al., 2012). In their study, Mellinghoff et al. (2012) also talk about factors that would
increase the therapeutic window of individual kinase inhibitors. It is stated that these are
different dosing schedules (e.g., intermittent or “pulsatile” dosing) (Shah et al. 2008) and
isoform-specific (e.g., PI3K) or mutant-specific (e.g., BRAF) compounds. The different
dosage levels effectiveness can be represented through cytotoxicity, and the results are
shown in Figure 8. The different dosage levels are the strongest candidate for positive
results, given it was this fact that was also highlighted in De Witte Hammer’s (2010)
study of kinase inhibitors with glioblastoma.
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Figure 8. (A) The results establish a relationship between concentration and
treatment duration with different kinase inhibitors. Cytotoxicity approached 100
percent in cells exposed continuously to 0.5 or 1 nM dasatinib (left) but was
substantially diminished with shorter exposure times. Similar results were observed
using concentrations of imatinib (1 μM) (right). (B) Assessment of BCR-ABL kinase
activity in K562 cells through analysis of phospho-CRKL and phospho-STAT5 following
treatment for 20 min with varying concentrations of dasatinib (left) and imatinib
(right). Figure from Shah et al. 2008.
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Glioma Treatment
Surgery

Standard treatment of glioblastoma includes maximal safe surgical resection, followed by
concurrent radiation with temozolomide (TMZ) (Temodar®), an oral alkylating
chemotherapy agent, and then adjuvant chemotherapy with TMZ (National
Comprehensive Cancer Network [NCCN], 2015). Although surgically removing the
tumor would seem like a promising therapy, extensive and complete surgical resection of
glioblastoma is difficult because these tumors are frequently invasive and are often in
eloquent areas of the brain, including areas that control speech, motor function, and the
senses (Davis, 2016). In the study conducted by Kuhnt et al. (2011), they focus on how
the more total resection for the patients possible, the more beneficial surgery will be in
glioblastoma therapy. They came to this conclusion by having 135 glioma patients
undergo tumor resection aided by 1.5T intraoperative MRI (iMRI) and integrated
multimodal navigation. The media survival was 14 months for patients who underwent an
extent of resection ≥98%, which is a significant improvement in patient survival. Kuhnt
et al. (2011) in their study came to the conclusion that results like this can be achieved
with iMRI and an intraoperative update of navigation data, along when performed on
patients <65 years of age. Although, Kuhnt et al. (2011) study showed promising results,
the prognosis for patients with GBM remains poor, with a median survival of 15 months
(Thakkar et al., 2014). In conclusion, both Thakkar et al. (2014) and Kuhnt et al. (2011)
found that patients with a lower age and higher performance status experience longer
survival.

Chemoradiation

Chemoradiation as means of glioblastoma treatment has been seen to produce more
promising results compared to chemotherapy and radiation alone. Although it is one of
the most popular choices of glioblastoma therapy, usually occurring around 4 weeks after
surgery, it holds the potential to cause more consequences than advantages. Shih and
Batchelor’s study (2017) analyzed the different techniques of chemoradiation practiced
(Adjuvant radiotherapy, treatment target, Intensity-modulated RT, etc.) and stated the
similar limitations found in each of them. It was found that the similar consequences of
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chemoradiation on glioblastoma include radiation-induced gliomas, neurocognitive
toxicity, RT-induced leukoencephalopathy, and endocrinopathies (Shih & Batchelor,
2016). Other side effects do occur because of chemoradiation, but they are more specific
to the route of chemoradiation chosen. Together with all these side effects, it was found
that the survival rate of patients was still low, with at 17 months after treatment 72% of
patients developed recurrent glioblastoma (Milano et al, 2010). Comparing Shih and
Batchelor’s (2016) findings to present chemoradiation practice, the adequate dose of
chemoradiation necessary to cause a high survival rate with low cytotoxicity levels is
required to maximize the survival benefit. Furthermore, these studies done in the past on
glioblastoma chemoradiation treatment, which included the benefits and limitations of it,
showed that further therapy options must be taken either before or after this to ensure an
increase in overall patient survival.
Temozolomide

Chemoradiation started showing much higher patient survival rates and less lethal side
effects when it contained Temozolomide (TMZ), rather than simple radiation alone,
shown in Figure 9. A separate study was conducted to test and analyze the results of
TMZ used in clinical practice, and the results from it were promising (Stupp et al., 2005).
This study was conducted with 573 patients who randomly received radiotherapy alone or
radiotherapy plus continuous daily temozolomide, followed by six cycles of adjuvant
temozolomide. At the median follow-up of 28 months, the median survival was 14.6
months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone
(Stupp et al., 2005). The two-year survival rate was 26.5 percent with radiotherapy plus
temozolomide and 10.4 percent with radiotherapy alone. These results were clinically
beneficial and showed statistically significant survival benefit with minimal additional
toxicity.

Another study looked at the combinatorial effect of high-linear transfer radiation (highLET) combined with Temozolomide, versus with conventional radiation like the study
above. Glioblastoma in treatment is known as a radioresistant tumor, meaning that even
when treated with conventional radiation the survival rates are still low. Barazzuol et al.
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(2012), believe that by using the new technology of high-LET combined with
Temozolomide on glioblastoma tumors, then this will show a much greater success rate
than what conventional radiation has shown in the past. To accomplish this, they tested
these combinations on four different human glioblastoma strains and analyzed their cell
survival, DNA damage and repair, and cell growth (Barazzuol et al., 2012). The results
from this study did not find any additive effects between high-LET and TMZ, but did
present data that supports the notion that the cytotoxic effects of TMZ and high-LET are
not likely to be correlated. This recognizes and supports past data that TMZ cytotoxicity
needs one or two cell divisions before DNA damage can be recognized. The cytotoxicity
of TMZ must be considered in both experimental or clinical procedures, and this data
further supports the positive effects of TMZ when in combination with either
radiotherapy or other chemotherapy drugs.

Temozolomide acts through DNA alkylation, and this analysis led to another strong
predictor of patient-related outcomes: the methylation of the MGMT gene (Stupp et al.,
2009). Methylated (not activated) MGMT exhibit compromised DNA repair, so when
MGMT becomes activated it can interfere with the effects of treatment. Radiotherapy and
alkylating chemotherapy exert their therapeutic effects by causing DNA damage,
cytotoxicity, and triggering apoptosis. Therefore, the expression of methylated MGMT is
beneficial for patients undergoing temozolomide chemotherapy and radiation. In this
study conducted by Stupp et al. (2009), the methylation of MGMT was a strong predictor
of better outcomes for temozolomide treatment.
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Figure 9. Results from clinical trial of patient treated with Radiotherapy plus Temozolomide vs. those
treated with Radiotherapy alone. The results showed a much higher probability of survival over a 42
month time span for those treated with Temozolomide vs. without. Figure from Stupp et al., 2005.
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Chapter 2
Materials and Methods
Blind Study
The first step in completing this combinatorial drug screen was determining which
Tyrosine Kinase Inhibitors proved to be the most successful. This was done by
completing a blind study over the course of the semesters. Blind studies are ones that can
be utilized in both the laboratory setting and also in clinical trials of medicine. Blind
studies by definition are studies done in which the subjects involved in the study do not
know which experimental condition they are receiving (Clinical Trials and Screening,
2020). There are both double-blind and single-blind studies that can be conducted, but in
the case of the drug screen it is only a single-blind study. In dealing with the Tyrosine
Kinase Inhibitors, the researchers are unaware of which Tyrosine Kinase Inhibitor they
are testing. It is done so by having the drugs named and labeled as a letter and numerical
value (i.e. A11). This blinding is especially important in experimental usage due to its
ability to prevent bias from influencing the results (Clinical Trials and Screening).

Many of the blind studies that are in the field of treating cancer, specifically with
glioblastoma, are experimented on the clinical trial side of medicine. These experiments
are done by recruiting a group of people that will allow for external validity to be applied
and who’s consent is properly given. An example of one of these blind studies took place
in 2017 with the combined use of TMZ with Rindopepimut (Weller et al., 2017).
Rindopepimut is a vaccine that targets the EFGR deletion mutation EGFRvIII. It does so
due to it being composed of a an EGFRvIII-specific peptide conjugated to keyhole limpet
haemocyanin (NCI Drug Dictionary). In this study patients with newly diagnose
EGFRvIII-expressing glioblastoma were treated with either Rindopepimut plus TMZ or
Rindopepimut plus control over the course of 6-12 cycles of treatment (Weller et al.,
2017). The results were collected using a randomized, double-blind trial, meaning that
neither the subject nor the researcher knew what treatment they were receiving. At the
end of the trial when compared to the control group, it was discovered that Rindopepimut
did not increase the survival rate in patients diagnosed with glioblastoma.
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A successful blind study which was done at the laboratory level looked at drug resistance
in Mycobacterium tuberculosis with the drugs isoniazid (INH) and rifampin (RMP). In
this study consecutive isolates of Mycobacterium tuberculosis were coded and sent to two
external laboratories for genotypic analysis of INH and RMP resistance by PCR-singlestrand conformation polymorphism (SSCP) analysis (Enriquez et al. 1997). The study
was considered blind given that the external laboratories were not aware of which of the
two drugs they would be testing, which allowed for no bias to negatively impact the
results. Through this study it was found that resistance can be accurately detected for
both INH and RMP when the study is limited to analyzing four main genetic regions
(Enriquez et al. 1997).

Dissection and Mounting
The phenotypes present in the fruit fly will be assessed from the larval to the pupae stage
to monitor growth regulation and cell proliferation in the adult brain from the third instar
larval stage following standard protocol. Dissection and mounting of the adult brain will
be necessary to track and get clear images of the progression of the tumor. Drosophila
larval brains are useful in modeling human brain degenerative diseases, mapping
neuronal circuitries in adult brains, and studying the molecular and cellular basis of
higher brain functions (Tito et al. 2016). In this drug screen dissection of the brain was
done on the third day of the larvae’s exposure to the specific drug. These drugs can either
be (a) a Tyrosine Kinase Inhibitor, (b) TMZ, or (c) Tyrosine Kinase Inhibitor plus TMZ.
The protocol calls for use of a Petri Dish and .55 forceps to ensure that a majority of the
eye and tracheal tissues normally associated with the brain are removed so no
interference is encountered in the later imaging steps (Tito et al. 2016).

The method used for proper dissection was to gently hold the larval body with one pair of
forceps, and with a second pair of forceps, hold the larval mouth hook. Pull the two pairs
of forceps apart gently to cause the mouth hook to detach from the body, allowing to the
brain to be isolated (Wu & Wu, 2006). Once brains are properly dissected, place them in
a 150μL phosphate-buffered saline (PBS) and 50μL Para-formaldehyde (PFA) solution to
fix for 20 minutes. Next add 1mL of cold 1xPBST (3.2 mM Na2HPO4, 0.5 mM NaH2PO4,
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1.3 mM KCl, 135 mM NaCl, 0.05% Triton X-100) and place on a rotator for 10 minutes.
After ten minutes, vacuum out PBST and repeat the wash two more times.

For mounting there were no antibodies used, so a primary and secondary stain were not
completed for the samples. Mounting was completed on a glass slide using .55 forceps to
isolate the unwanted tissues from around the brains. Once properly isolated, the brains
were coated in Vectashield to inhibit the rapid photobleaching of fluorescent proteins and
fluorescent dyes (VECTASHIELD®, 2020). The brains were then organized in a line, a
cover slip was placed properly on top, and nail polish was used to inhibit the cover slip
from sliding. Mounted slides were then labeled and placed in a -20˙C freezer until
imaging could be completed.

Imaging
The samples taken from the Drosophila models, once properly dissected and mounted,
will be scanned in the Laser Confocal Scanning microscope. The adult flies will be
photographed by using Olympus Bx51 Florescence microscope or Zeiss Apotome. The
images that are generated from these microscopes will be used to more clearly track the
growth of the tumor as well as be analyzed for statistical significance using Image J
programming. Images will be analyzed based on both their glial cell presence and size
and shape of the brain itself.
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Layout of Drug Screen

Tyrosine Kinase Inhibitors
To analyze the effects of Tyrosine Kinase Inhibitors in treating glioblastoma, dissection,
mounting and imaging of the brain were completed. The stocks of Pteni; Rasv12, and
Repo Gal4 UAS-GFP served as controls, and the F1 larvae from the Pteni;Rasv12x Repo
GFP cross constituted the experimental samples in which glioma was induced in the
larval CNS. All inhibitors were first tested at the 300μL dose. By following the protocol
that is demonstrated in Figure 1, the brains were analyzed for two characteristics: (a) the
number of glial cells left after treatment, and (b) the change in overall size of the brains.
A successful treatment of Tyrosine Kinase Inhibitors would show the glioma brains
shrinking back to a moderate normal size, and also have the glial cell population decrease
(Figure 2). A negative effect of the drug would either show no change from the original
or a sharp increase in glial cells and a larger abnormal brain lobe shape (Figure 2). The
inhibitors that proved to show success will be tested at different concentrations and also
be used in the combinatorial drug screen with TMZ.
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Figure 10. The seven-step protocol followed when testing both the Tyrosine Kinase Inhibitors
and TMZ on the Drosophila glioma model.
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Figure 11. These are results used to help determine if a specific tyrosine kinase
inhibitor showcases suppression, enhancement, or no change in tumor size and
shape when compared to the control groups. The control group is a normal, healthy
fly brain.
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Combinatorial Drug Screen
Given that both TMZ and the tested Tyrosine Kinase Inhibitors showed positive results
when used on the Drosophila glioma model separately, they went on to be further tested
when used in combination. The five successful tyrosine kinase inhibitors were tested with
the control value of TMZ (3mM) at a set value of 300μM on Repo GFP and Pteni;
Rasv12x Repo GFP. The five tyrosine kinase inhibitors were A4, A9, B4, B6, and B9. The
300μM was chosen to test for the initial success of TMZ combined with the kinase
inhibitors. These set values of TMZ and kinase inhibitors were added to the larvae’s food
by protocol, and the success of the screen was analyzed the same way the initial TMZ
screen was. On day-three 50 larvae were added into the drug concentrated food, and it
was starting on day-five that the larvae could begin to get analyzed and counted. By
counting the amount of small, medium, large tumors and possible alive flies present, the
combination was determined to be successful at this concentration range.
The most successful of these combinations was A9 (300μM) + TMZ (3mM). To
determine if A9 would be more successful at a different concentration range, it was tested
by changing the concentration using a log scale. These log scale concentrations tested
were 10μM, 30μM, 100μM, and 300μM. Over the course of several weeks these
combinations were tested and analyzed by counting the number of different tumors
present in the larvae and the vitality of the larvae was also analyzed.

P a g e | 29

Chapter 3
Results
Tyrosine Kinase Results
The primary drug screen that has looked solely at the effectiveness of Tyrosine Kinase
Inhibitors has been an entire group effort between students in Dr. Kango-Singh’s lab.
This is still an ongoing project as well to continue to determine tyrosine kinase inhibitors
that show suppression in our Drosophila glioma model. Like stated earlier, the results of
tyrosine kinase inhibitors by themselves are tested through dissection and mounting of
the larval brains. From this analysis and comparing images of the brains, it was
determined there were six inhibitors that showed strong suppression effects on our tumor
model. These drugs were: P1A4, P1A9, P1B4, P1B6, P1B9 and P1G10. The results from
one of these successful drugs, P1G10, is pictured in Figure 12. P1G10 is determined to
show suppression due to that both brain lobes and the ventral nerve cord (VNC)
decreased relatively close to the control, and the glia cell population has not increased.
All other tyrosine kinase inhibitors listed above also followed a similar suppression trend
as seen in P1G10.
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Figure 12. Results from our glioma tumor being tested with Tyrosine Kinase Inhibitor
P1G10. Results were looked at over the course of three days to determine effectiveness.
Over the course of the analysis period P1G10 continued to show strong suppression results
of the tumor.
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Initial Temozolomide Screen
The initial screen of TMZ was done in order to test the concentration that it works best at
in our Drosophila glioma model. TMZ was tested using a log scale from values 101000μM, and then an additional 3mM and 5mM. To analyze the effects that TMZ has on
the Drosophila glioma model, mounting and dissection will not take place. Given that
TMZ is a DNA alkylating agent, most of the larvae will not progress into the alive fly
stage but will be halted in their growth at the pupal stage. The growth arrest phenotypes
were categorized based on the tumor size which was tracked by the expression of GFP.
The pupae were categorized as small, medium, and large tumors and the effect of
particular concentration of TMZ was tested.

The different tumor sizes along with the control group can be seen in Figure 13. A small
tumor is observed when the larvae progresses all the way to producing red eyes and
wings but does not progress all the way to hatching. A medium tumor takes up more a
presence within the larvae but has not completely taken over, as what would be seen in a
large tumor. A large tumor completely takes over the larvae and produces necrotic spots
along the pupae. With a large tumor it looks as if a larva never even formed within the
pupal casing, but instead always remained empty. The TMZ concentration with the
largest amount of small tumor larvae, along with the larvae that show the greatest vitality,
will be seen as the most successful concentration of TMZ.

Another aspect that was analyzed when determining the successful TMZ concentration
was the vitality of the larvae after treatment to the drug. TMZ effectiveness was tested by
adding fifty larvae from each stock to every concentration tested. The larvae that would
showcase the most vitality after being treated would lend to it being determined a
successful concentration of treatment. High vitality was determined by the greatest
number of larvae that came up from food concentrated with TMZ. If only ten out of fifty
larvae come up from the food after treatment, this would showcase low vitality given a
majority of larvae died due to the drug concentration. This death could either occur from
the concentration being too low to have an effect on the glioma, or that it was too high
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and was cytotoxic. The concentration of TMZ that shows the most success will go on to
be used as the control value for the combinatorial drug screens between TMZ and the
experimentally determined effective Tyrosine Kinase Inhibitors.
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Figure 13. Images of a small, medium, and large tumor after treatment with the effective 3mM
concentration of TMZ. The small tumor is identified by its presence of both wings and eye disks
within the pupal casing. Large and medium tumors are distinguished based on the large tumors
having necrotic spots presence and also less larvae present in the case.
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Testing the effects of Temozolomide on glioma growth
The effective control concentration of Temozolomide when used on the Drosophila
glioma model (Pteni; Rasv12x Repo GFP) was determined to be 3mM. This was
determined due to the 3mM concentration having the largest number of alive flies (9) and
small tumors (7) present after treating with the drug. Given that other concentrations
tested also had a large number of small tumors present, 3mM was selected due to the
large number of alive flies that hatched over the time of observation. Alive flies are
highly uncommon when in treatment with TMZ due to TMZ acting as an alkylating
agent, so the presence of them gains immense interest. The least of effective
concentration of TMZ was 1.5mM, given that this had the largest number of large tumors
present (17) after treatment and no live flies hatching from their pupal casing. The results
from the different concentrations can be viewed in Table 1. Images of an example of the
small, medium, and large tumors from the effective 3mM concentration can be seen in
Figure 13.
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Table 1: The different tumor counts in the Drosophila after treatment with different concentrations of
TMZ. It was through these results and the large amount of both small tumor and alive flies seen at
the 3mM range that made it be chosen as the control value for future experiments containing TMZ
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Tyrosine Kinase and Temozolomide Combinatorial Results
In the combinatorial research there was a total of five different tyrosine kinase inhibitors
tested along with the concentration value of 3mM TMZ. The five tyrosine kinase
inhibitors that went on to be further tested at the 300μM concentration level were: A4,
A9, B4, B6, and B9. Out of these combinations A4(300μM) + TMZ(3mM) was one
combination that showed significant suppression of the tumor. This suppression was
determined based off the significant number of small tumors and alive flies present after
addition to the drug. As seen in Table 2, there was a total of 9 small tumors and 3 alive
flies present. Although there was still a sizable number of large tumors present (15 total),
it was the fact that there were alive flies that hatched that kept promise of success of this
specific combination. Another combination that stood out as being a potential successful
suppressor was B9(300μM) + TMZ(3mM). Looking at both Table 2 and Graph 1, the
most substantial result from this combination is the large number of alive flies that
hatched out of the treated fifty. There was a total of ten alive flies that hatched, which is
the most out of any other combination tested. Given that both of these showed substantial
results, it was the A4(300μM) + TMZ(3mM) combination that was selected first to go
through a more thorough testing of different concentrations that might be more effective
than the 300μM value.
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Pteni; Rasv12 x Repo Combinatorial Drug Results of Number of Tumors
Present with Various Tyrosine Kinase Inhibitors

Drug Type
A4 (300μM) +

Small Tumor

Medium Tumor

Large Tumor

Alive Flies

9

7

19

2

9

10

15

3

2

9

12

8

17

3

15

3

12

9

9

10

TMZ (3mM)
A9 (300μM) +
TMZ (3mM)
B4 (300μM) +
TMZ (3mM)
B6(300μM) +
TMZ (3mM)
B9 (300μM) +
TMZ (3mM)
Table 2. This table is showing the different number of small, medium, and large tumors present in
the larvae after each individual concentration of Tyrosine Kinase Inhibitor (300nm) + TMZ (3mM)
was added. The total number of larvae added to each combination was 50 and the type of tumor was
counted and recorded in the table above to help track both the success of the combination and
vitality of the drug.
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Graph 1. This graph shows the results from the different tyrosine kinase inhibitors
when combined with 3mM TMZ. This graph was creating using the values in Table 2.
Looking at the difference in size of tumor it was both A9 and B9 that showcased the
most success as a tumor suppressor when aligned on a side by side graph like above.
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Various concentrations of A9 + Temozolomide (300mM) Results
To further test the success that the Tyrosine Kinase Inhibitor A9 + TMZ could have, it
was selected and observed separately using different concentration values. The
concentrations selected were based on a log scale and the same amount of fifty larvae
were added to each. Looking at the table and graph below there were significant results
from the data collection. One of these results was the high success seen in the
concentration value of 100μM versus the originally tested 300μM. In the 100μM
concentration value there is a large number of small tumors present (18) and a significant
number of alive flies (8) when compared to the medium and large tumor presence at this
concentration (6 and 5, respectively) as seen in Table 3.

Another concentration that showed promise due to the substantial amount of suppression
present was the A9 (10μM) + TMZ (3mM). Looking at Graph 2, it is this combination
that shows the largest number of small tumors present when compared to the other three
concentrations of A9 tested. Given this high number of large tumors present, it shows
potential to be looked into through further testing. When compared to the results of A9
(100μM) + TMZ (3mM) that were described earlier, the 10μM concentration
combination still did not succeed the effects of it due to the very low number of alive
flies present and not significant halting of the tumor growth. The presence of alive flies at
these concentrations hold much more importance in showing the effects it has on the
tumor than the number of small tumors present. Taking this into consideration, it is the
large number of alive flies that hatched (as seen in the 100μM combination) that proves
more success than a large number of small tumors (as seen in the 10μM).
The concentration that showed the least amount of suppression was at the 300μM level,
which was a significant result given it was this concentration value that showed the most
promise in the original combinatorial study. This combination value of A9 (300μM) +
TMZ (3mM) was determined to have the least amount of suppression compared to the
others based off of it having the highest number of large tumors present when compared
to both the small, medium, and alive flies at its same concentration value. With this
leading amount of 15 large tumors present as seen in Graph 2, it was deemed that the
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combination was not as successful as originally thought it was. This decrease in success
is hypothesized to be due to the amount of 300μM being too high of a concentration for it
to show any significant results. The concentration of drug starts to either cause
cytotoxicity to the larvae or the concentration is too large for it to produce a successful
suppression effect.
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Pteni; Rasv12 x Repo Results of Number of Tumors from A9 at
various combinations + 3mM TMZ
Drug Type
A9 (10μM) + TMZ

Small Tumor

Medium Tumor

Large Tumor

Alive Flies

27

7

2

1

11

2

8

9

18

6

5

8

9

10

15

3

(3mM)
A9 (30μM) + TMZ
(3mM)
A9 (100μM) + TMZ
(3mM)
A9 (300μM) + TMZ
(3mM)
Table 2. This table is showing the different number of small, medium, and large tumors
present in the larvae after each individual concentration of Tyrosine Kinase Inhibitor A9 +
TMZ (3mM) was added. The total number of larvae added to each combination was 50 and
the type of tumor was counted and recorded in the table above to help track both the success
of the combination and vitality of the drug.
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Graph 1. This graph shows the results from the tyrosine kinase inhibitor A9 at different
concentrations on a log scale when it is combined with the control value of TMZ at 3mM. This
graph was creating using the values in Table 3. Looking at the difference in size of tumor it was
the A9 (100μM) that showcased the most success.

P a g e | 43

Conclusion
In conclusion we found that there were significant combinatorial effects when both the
Tyrosine Kinase Inhibitor and Temozolomide were added to treat glioblastoma. With the
poor prognosis that Glioblastoma has, these results are significant in the possibility of
helping reduce these deathly diagnoses. One of the initial takeaways from these results is
the promise that TMZ by itself showed in our Drosophila model. Given that TMZ is not
supposed to have any alive flies hatch due to it acting as a DNA alkylating agent, it was
surprising to see so many appear at the 3mM range. This result could be due to the
amount of TMZ treating the glioma was not enough for it to become lethal to larvae,
while at the same time not allowing all of the DNA to become alkylated. The presence of
alive flies was something that carried on into the other experiments containing TMZ,
which helped support the validity that the alive flies at 3mM were not an outlier. It was
the effectiveness of TMZ alone that was seen in our Drosophila glioma model that helped
further support its effectiveness as a chemotherapy drug, which is how it is currently
being used in treatment of glioblastoma.

The effective concentration of TMZ (3mM) was combined with the Tyrosine Kinase
Inhibitors that proved successful throughout past experiments in order to determine if
tumor suppression could be seen in combination of drugs. The five successful tyrosine
inhibitors were initially tested at a control value of 300μM when in combination with the
3mM TMZ. The findings from these results showed that there were significant
suppression effects in some of the combination of Tyrosine Kinase Inhibitors and TMZ.
It was in the combinations of A9 (10μM) + TMZ (3mM) and B9 (10μM) + TMZ (3mM)
that the most impressive results were found. Both of these concentrations not only had a
significant number of small tumors present when in comparison to the medium and small
tumors, but they also had a noticeable number of alive flies’ present. Although the high
presence of small tumors does lead to the combination being a tumor suppressor, the
presence of alive flies holds more weight when it comes to analyzing results. This is due
to it being relatively uncommon in the treatment of TMZ, so the presence of them leads
to the drug treating the glioma enough to allow the larvae to fully hatch. When looking at
the combinations, the high frequency of alive flies could be due to the positive effect the
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Tyrosine Kinase Inhibitor has on suppressing the glioma, and this effect could override
the alkylating effect of the TMZ present. Also, TMZ alone at 3mM showed a high
percentage of alive flies, so this concentration from past experiments is not known to
fully alkylate all the DNA present in the larvae. It was the success that was found
throughout this combinatorial experiment that led to further testing with these two
chemotherapy drugs.

Isolating A9 at different combinations with TMZ (3mM) also showed significant results
in the suppression of the glioma tumor. A9 was selected for isolation due to the strong
tumor suppression results it showed in the earlier experiment discussed above. Looking at
the results, it was clear to see that the initially tested 300μM of Tyrosine Kinase Inhibitor
was not the best concentration value when combined with the control TMZ. Looking at
Graph 2 it is clear to see the varying results across the four tested concentration ranges.
Given that it was tested on a log scale there is some variability between all of the values,
but the most effective concentration tested came to be the A9 (100μM) + TMZ (3mM).
This was a lesser concentration than the 300μM initially tested, which leads to the
conclusion that A9 at a lesser concentration is more effective than at larger ones
(300μM<x). By determining the concentration range that this specific drug works best,
future testing could be done to help narrow the specific range down even further.

When studying the Tyrosine Kinase Inhibitors in the primary drug screen there were over
seventy drugs beings tested on the Drosophila glioma model. The need to conduct this
blind study on the variety of different tyrosine kinase inhibitors was due to each
activating a different protein pathway in order to exert their effect on the tumor. Looking
at the results it was clear to see that each inhibitor tested did not show the same results,
but instead showed a range of suppression and enhancement on the glioma. These results
allowed for it to be further confirmed that although a category of treatment drugs have
the same end result (i.e. adding a phosphate group), they do not activate the same
pathways to get there. This activation of different pathways allows for different effects to
be placed on the tumors which creates a wide variety of choices to choose in treatment of
an individual suffering glioblastoma. To narrow down which protein pathways are
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specifically activated in the successful suppression tyrosine kinase inhibitors tested,
Western Blotting must be run. Western Blotting will be able to show the exact proteins
that are activated in the pathway, and these results can be compared to other drugs that
also use the same pathway. This comparison will allow for a quicker selection of drugs to
be tested and a connection between a wider range of chemotherapy drugs.

Finally, given that this was a primary drug screen to test the initial effects of both
tyrosine kinase inhibitors and TMZ on glioblastoma, there is further testing needing to be
done to determine the overall effectiveness on other model organisms. The results of
these combinatorial results showed success in our Drosophila glioma model, which
leaves the question open if these results can be replicated in other systems. These
combinations found to be successful in reducing the tumor in the fruit fly are worth
testing in other organisms (i.e. mice). Mice are a helpful model in determining the
success a drug would have in humans due to them sharing 85% of its genomes with
humans and their genes being able to be added or removed easily for further testing (Why
Mouse Matters, 2010). If the results are replicated in a different organism’s system, then

more credibility is added to the ability of the drug to act as a suppressor and therefore
would show more promise to continue testing into clinical trials. Clinical trials are the
last in drug testing to determine the overall success. If our combinatorial chemotherapy
treatment makes it to clinical trials and continues to show suppression in human models,
this shows great promise and confirms the success of this treatment in suppression
glioblastoma tumors.
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